Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-3427?

AZD-3427 is commercialized by AstraZeneca, with a leading Phase II program in Pulmonary Hypertension.

Mar 13, 2024 - 18:29
AZD-3427 is commercialized by AstraZeneca, with a leading Phase II program in Pulmonary Hypertension.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of Johnson & John...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA ...

Aug 13, 2024

Inside the efforts to rescue a rare disease gene therapy 

Inside the efforts to rescue a rare disease gene therapy 

Jul 28, 2024

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux

Biotechs investigate ways to adapt to new clinical tria...

Sep 20, 2024